AI-Augmented Diagnostic Assessment With ENLIGHT Versus Independent Pathologist Review
Part of paid clinical trials in Boston, Massachusetts.
- Sponsor
- Harvard Medical School (HMS and HSDM)
- Study ID
- NCT07741058
- Status
- Enrolling By Invitation
Conditions
- Cancer
Eligibility Criteria
- Sex
- ALL
- Age
- N/A - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Unaided Review First, Then AI as Double-Check, Then AI as First-Look. — BEHAVIORALReaders first complete Block X (Unaided) on their assigned subset SX. They then complete Block Y1 (AI as Double-Check) on two separate subsets: SY1a (AI prediction-only as Double-Check) and SY1b (AI prediction-with-explanation as Double-Check). Within Block Y1, the order of SY1a and SY1b is randomized. They then complete Block Y2 (AI as First-Look) on two separate subsets: SY2a (AI prediction-only as First-Look) and SY2b (AI prediction-with-explanation as First-Look). Within Block Y2, the order of SY2a and SY2b is randomized. For each reader, SX, SY1a, SY1b, SY2a, and SY2b are disjoint.
- Unaided Review First, Then AI as First-Look, Then AI as Double-Check. — BEHAVIORALReaders first complete Block X (Unaided) on their assigned subset SX. They then complete Block Y2 (AI as First-Look) on two separate subsets: SY2a (AI prediction-only as First-Look) and SY2b (AI prediction-with-explanation as First-Look). Within Block Y2, the order of SY2a and SY2b is randomized. They then complete Block Y1 (AI as Double-Check) on two separate subsets: SY1a (AI prediction-only as Double-Check) and SY1b (AI prediction-with-explanation as Double-Check). Within Block Y1, the order of SY1a and SY1b is randomized. For each reader, SX, SY1a, SY1b, SY2a, and SY2b are disjoint.
- AI as Double-Check First, Then AI as First-Look, Then Unaided Review. — BEHAVIORALReaders first complete Block Y1 (AI as Double-Check) on two separate subsets: SY1a (AI prediction-only as Double-Check) and SY1b (AI prediction-with-explanation as Double-Check). Within Block Y1, the order of SY1a and SY1b is randomized. They then complete Block Y2 (AI as First-Look) on two separate subsets: SY2a (AI prediction-only as First-Look) and SY2b (AI prediction-with-explanation as First-Look). Within Block Y2, the order of SY2a and SY2b is randomized. Then readers complete Block X (Unaided) on their assigned subset SX. For each reader, SX, SY1a, SY1b, SY2a, and SY2b are disjoint.
- AI as First-Look First, Then AI as Double-Check, Then Unaided Review. — BEHAVIORALReaders first complete Block Y2 (AI as First-Look) on two separate subsets: SY2a (AI prediction-only as First-Look) and SY2b (AI prediction-with-explanation as First-Look). Within Block Y2, the order of SY2a and SY2b is randomized. They then complete Block Y1 (AI as Double-Check) on two separate subsets: SY1a (AI prediction-only as Double-Check) and SY1b (AI prediction-with-explanation as Double-Check). Within Block Y1, the order of SY1a and SY1b is randomized. Then readers complete Block X (Unaided) on their assigned subset SX. For each reader, SX, SY1a, SY1b, SY2a, and SY2b are disjoint.
Study Details
This study will evaluate whether artificial intelligence (AI) can enhance clinicians' accuracy, efficiency, and confidence in distinguishing lung adenocarcinoma (LUAD) from lung squamous cell carcinoma (LUSC) and kidney renal papillary cell carcinoma (KIRP) from kidney renal clear cell carcinoma (KIRC) using digitized pathology slides. These subtype classifications are routinely performed by pathologists but can be challenging and time-consuming, particularly in difficult cases. During the study, participating clinicians will review lung and kidney pathology slides under three different conditions: * Unaided Review: Diagnosis without AI assistance. * AI as Double-Check: The clinician first makes an independent diagnosis, after which the AI-generated diagnosis (prediction only or prediction with explanation) is revealed for review. * AI as First-Look: The AI-generated diagnosis (prediction only or prediction with explanation) is presented before the clinician begins the review. Clinicians will be randomly assigned to different review sequences to minimize potential order effects. This study design will enable us to assess the impact of AI assistance on diagnostic accuracy, interpretation time, and clinician confidence.
Key Dates
- First listed
- Aug 3, 2026
- Start date
- Jul 31, 2026
- Status verified
- Jul 2026
- Primary completion
- Aug 31, 2026
- Completion
- Aug 31, 2026
Study Design
- Enrollment
- 25 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- CROSSOVER
- Primary purpose
- DIAGNOSTIC
Arms
- Active Comparator: Unaided Review First, Then AI as Double-Check, Then AI as First-Look.Readers first complete Block X (Unaided) on their assigned subset SX. They then complete Block Y1 (AI as Double-Check) on two separate subsets: SY1a (AI prediction-only as Double-Check) and SY1b (AI prediction-with-explanation as Double-Check). Within Block Y1, the order of SY1a and SY1b is randomized. They then complete Block Y2 (AI as First-Look) on two separate subsets: SY2a (AI prediction-only as First-Look) and SY2b (AI prediction-with-explanation as First-Look). Within Block Y2, the order of SY2a and SY2b is randomized. For each reader, each of the five subsets (SX, SY1a, SY1b, SY2a, and SY2b) comprises up to 80 slides: up to 40 slides from LUAD-LUSC and up to 40 slides from KIRP-KIRC.
- Active Comparator: Unaided Review First, Then AI as First-Look, Then AI as Double-Check.Readers first complete Block X (Unaided) on their assigned subset SX. They then complete Block Y2 (AI as First-Look) on two separate subsets: SY2a (AI prediction-only as First-Look) and SY2b (AI prediction-with-explanation as First-Look). Within Block Y2, the order of SY2a and SY2b is randomized. They then complete Block Y1 (AI as Double-Check) on two separate subsets: SY1a (AI prediction-only as Double-Check) and SY1b (AI prediction-with-explanation as Double-Check). Within Block Y1, the order of SY1a and SY1b is randomized. For each reader, each of the five subsets (SX, SY1a, SY1b, SY2a, and SY2b) comprises up to 80 slides: up to 40 slides from LUAD-LUSC and up to 40 slides from KIRP-KIRC.
- Active Comparator: AI as Double-Check Review First, Then AI as First-Look, Then Unaided Review.Readers first complete Block Y1 (AI as Double-Check) on two separate subsets: SY1a (AI prediction-only as Double-Check) and SY1b (AI prediction-with-explanation as Double-Check). Within Block Y1, the order of SY1a and SY1b is randomized. They then complete Block Y2 (AI as First-Look) on two separate subsets: SY2a (AI prediction-only as First-Look) and SY2b (AI prediction-with-explanation as First-Look). Within Block Y2, the order of SY2a and SY2b is randomized. Then readers complete Block X (Unaided) on their assigned subset SX. For each reader, each of the five subsets (SX, SY1a, SY1b, SY2a, and SY2b) comprises up to 80 slides: up to 40 slides from LUAD-LUSC and up to 40 slides from KIRP-KIRC.
- Active Comparator: AI as First-Look Review First, Then AI as Double-Check, Then Unaided Review.Readers first complete Block Y2 (AI as First-Look) on two separate subsets: SY2a (AI prediction-only as First-Look) and SY2b (AI prediction-with-explanation as First-Look). Within Block Y2, the order of SY2a and SY2b is randomized. They then complete Block Y1 (AI as Double-Check) on two separate subsets: SY1a (AI prediction-only as Double-Check) and SY1b (AI prediction-with-explanation as Double-Check). Within Block Y1, the order of SY1a and SY1b is randomized. Then readers complete Block X (Unaided) on their assigned subset SX. For each reader, each of the five subsets (SX, SY1a, SY1b, SY2a, and SY2b) comprises up to 80 slides: up to 40 slides from LUAD-LUSC and up to 40 slides from KIRP-KIRC.
Primary Outcome Measure
Diagnostic performance of cancers [ Time Frame: Periprocedural (at the time of slide review) ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Harvard Medical School, | Boston | Massachusetts | 02115 | - |
Find similar trials in Boston, MA
Related Studies
- Evaluation of Non-Invasive Assays for the Detection of Urothelial CancerRecruiting · Lahey Clinic · Burlington, Massachusetts
- Childhood Cancer Survivor StudyRecruiting · St. Jude Children's Research Hospital · Birmingham, Alabama
- Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6PHASE2 · Recruiting · Dana-Farber Cancer Institute · Boston, Massachusetts
- SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and RegistryRecruiting · Massive Bio, Inc. · Birmingham, Alabama